Primary and secondary efficacy endpoints
After a median follow-up of 14.7 months (range: 0.2–25.1 months), the primary endpoint was met with 61.0% (95% confidence interval (CI): 51.8–69.6) of patients having a confirmed objective response per BICR. The best overall response is summarized in Fig. 